It has been shown that all patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) overexpress CD123. In this video, Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, talks on IMGN632, a novel CD123-targeting antibody-drug conjugate (ADC) in development for the treatment of patients with BPDCN. A Phase I/II clinical trial is currently evaluating this agent in both the frontline and relapsed/refractory (R/R) settings (NCT03386513) and is showing promising safety and efficacy results. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.